Actithera is pioneering chemistries in radioligand therapy that extend tumor residence time, creating differentiated candidates like its lead fibroblast activation protein-targeted compound.

Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Bond polarity, driven by differences in electronegativity, explains why some molecules dissolve in water, why others don’t, and why substances have different boiling points. Polar bonds have unequal ...

Molly Gibson, PhD, has focused her attention on building companies at the intersection of AI and life sciences for the past decade, having co-founded both Generate: Biomedicines and Lila Sciences.

TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include limited mutation coverage and poor tolerability ...